| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/12/264:00 PM | -$1.01 | -$1.05GAAP | -4.0% | +9% | — | $0 | — | — | |
| Q2 '26 | 8/13/264:00 PM | -$0.96 | -$1.05GAAP | -9.4% | -2% | — | $0 | — | — | |
| Q1 '26 | 5/7/264:00 PM | -$1.00 | -$0.94GAAP | +6.0% | +14% | — | $0 | — | — | |
| Q4 '25 | 3/31/264:45 PM | -$1.04 | -$1.04GAAP | 0.0% | -24% | — | $0 | — | — | |
| Q3 '25 | 11/13/254:00 PM | -$1.05 | -$1.16GAAP | -10.5% | -38% | — | $0 | — | — | |
| Q2 '25 | 8/13/254:00 PM | -$1.03 | -$1.03GAAP | 0.0% | -20% | — | $0 | — | — | |
| Q1 '25 | 5/14/254:00 PM | -$0.87 | -$1.09GAAP | -25.3% | -33% | — | $0 | — | — |
GAAP = diluted EPS as filed with the SEC.